J Yahalom

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma
    Gaurav D Shah
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4730-5. 2007
  2. doi request reprint Does radiotherapy still have a place in Hodgkin lymphoma?
    Joachim Yahalom
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Hematol Malig Rep 4:117-24. 2009
  3. ncbi request reprint Favorable early-stage Hodgkin lymphoma
    Joachim Yahalom
    Radiation Oncology in Medicine Department, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 4:233-40. 2006
  4. doi request reprint Role of radiation therapy in Hodgkin's lymphoma
    Joachim Yahalom
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
    Cancer J 15:155-60. 2009
  5. doi request reprint Long-term cardiac and pulmonary complications of cancer therapy
    Joachim Yahalom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 22:305-18, vii. 2008
  6. ncbi request reprint Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease
    Joachim Yahalom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 4:415-23. 2002
  7. ncbi request reprint The involved field is back: issues in delineating the radiation field in Hodgkin's disease
    J Yahalom
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Ann Oncol 13:79-83. 2002
  8. ncbi request reprint Long-term cardiac and pulmonary complications of cancer therapy
    Joachim Yahalom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Heart Fail Clin 7:403-11. 2011
  9. doi request reprint Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity
    Bradford S Hoppe
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10165, USA
    J Clin Oncol 26:1858-64. 2008
  10. ncbi request reprint Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat
    Joachim Yahalom
    Lymphoma Disease Management Team and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 48:1667-9. 2007

Detail Information

Publications70

  1. ncbi request reprint Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma
    Gaurav D Shah
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4730-5. 2007
    ....
  2. doi request reprint Does radiotherapy still have a place in Hodgkin lymphoma?
    Joachim Yahalom
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Hematol Malig Rep 4:117-24. 2009
    ..This review discusses controversial issues regarding RT, the studies that have addressed them, the new indications for integrating RT, and the safety of minimizing the radiation field and dose...
  3. ncbi request reprint Favorable early-stage Hodgkin lymphoma
    Joachim Yahalom
    Radiation Oncology in Medicine Department, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 4:233-40. 2006
    ..Although combined modality is the standard preferred treatment for favorable disease, radiation therapy alone or chemotherapy alone could be considered under special circumstances or as part of an investigational protocol...
  4. doi request reprint Role of radiation therapy in Hodgkin's lymphoma
    Joachim Yahalom
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
    Cancer J 15:155-60. 2009
    ..Short chemotherapy supplemented with mini-radiotherapy constitutes a highly effective and safe treatment of HL, particularly in early stages...
  5. doi request reprint Long-term cardiac and pulmonary complications of cancer therapy
    Joachim Yahalom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 22:305-18, vii. 2008
    ..Potential preventive measures for high-risk patients are of increasing interest but remain experimental...
  6. ncbi request reprint Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease
    Joachim Yahalom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 4:415-23. 2002
    ..The new principles of integrating radiotherapy into a combined-modality regimen for HD at different prognostic stages are reviewed here, along with the effect of this new role on radiation field size and design...
  7. ncbi request reprint The involved field is back: issues in delineating the radiation field in Hodgkin's disease
    J Yahalom
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Ann Oncol 13:79-83. 2002
    ..In this manuscript we review the comeback of the involved field, address design questions and offer field borders for common disease sites...
  8. ncbi request reprint Long-term cardiac and pulmonary complications of cancer therapy
    Joachim Yahalom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Heart Fail Clin 7:403-11. 2011
    ..Potential preventive measures for high-risk patients are of increasing interest but remain experimental...
  9. doi request reprint Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity
    Bradford S Hoppe
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10165, USA
    J Clin Oncol 26:1858-64. 2008
    ..To analyze outcome, prognostic factors, and toxicities in patients with diffuse large-cell lymphoma (DLCL) who received involved-field radiotherapy (IFRT) before high-dose chemotherapy with autologous stem-cell rescue (ASCR)...
  10. ncbi request reprint Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat
    Joachim Yahalom
    Lymphoma Disease Management Team and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 48:1667-9. 2007
  11. ncbi request reprint Radiation therapy in the treatment of lymphoma
    J Yahalom
    Memorial Sloan Kettering Cancer Center, and Radiation Oncology in Medicine, Cornell University Medical College, New York, NY, USA
    Curr Opin Oncol 11:370-4. 1999
    ..Preliminary data suggest that even in an advanced-stage, intermediate-grade, adjuvant radiotherapy to bulky sites may improve outcome. This issue merits further study...
  12. doi request reprint Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience
    S M Edwards-Bennett
    Lymphoma Disease Management Team and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Oncol 21:574-81. 2010
    ..We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data...
  13. ncbi request reprint Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma
    T Kewalramani
    Department of Medicine, Lymphoma and Hematology Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bone Marrow Transplant 32:673-9. 2003
    ....
  14. ncbi request reprint Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
    Paul A Hamlin
    Lymphoma and Hematology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 350, 1275 York Ave, New York, NY, 10021
    Blood 102:1989-96. 2003
    ..This powerful prognostic instrument should be used to evaluate new treatment approaches and to compare results of different regimens...
  15. doi request reprint The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma
    B S Hoppe
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bone Marrow Transplant 43:941-8. 2009
    ..006). These outcomes confirm the important prognostic value of FDG-PET scans before undergoing HDT/ASCR. It also suggests that the role of IFRT should be evaluated further...
  16. ncbi request reprint The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide
    C S Portlock
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 15:1495-503. 2004
    ..The NHL-15 protocol is a novel, dose-intense, dose-dense, sequential chemotherapy program developed to improve outcome in advanced, aggressive non-Hodgkin's lymphomas...
  17. ncbi request reprint Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
    C H Moskowitz
    Lymphoma and Hematology Services, Department of Medicine, and Departments of Radiotherapy, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 17:3776-85. 1999
    ....
  18. ncbi request reprint R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy
    Jeffrey L Halaas
    Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Leuk Lymphoma 46:541-7. 2005
    ..Whether adding rituximab and increasing dose intensity improves survival over either alone will require randomized studies...
  19. ncbi request reprint Treatment for primary CNS lymphoma: the next step
    L E Abrey
    Departments of Neurology and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3144-50. 2000
    ..The reported protocol was designed to optimize and enhance the chemotherapeutic component of treatment...
  20. ncbi request reprint Delayed neurotoxicity in primary central nervous system lymphoma
    Antonio M P Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Neurol 62:1595-600. 2005
    ..This delayed neurotoxicity has been poorly defined in the literature, and the underlying mechanisms are unknown...
  21. ncbi request reprint Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up
    Antonio M P Omuro
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Neurology 64:69-74. 2005
    ..To assess the efficacy and safety of a preradiation chemotherapy regimen in patients with primary CNS lymphoma (PCNSL), with emphasis on long-term outcomes...
  22. ncbi request reprint Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma
    Andreas F Hottinger
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Neurology 69:1178-82. 2007
    ..Consequently, patients are often treated with chemotherapy alone, and WBRT is deferred until relapse...
  23. ncbi request reprint Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5711-5. 2006
    ....
  24. ncbi request reprint Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients
    Kathryn Beal
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:2652-6. 2006
    ....
  25. ncbi request reprint Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT)
    Benjamin D Rosenbluth
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 65:1185-91. 2006
    ..We studied clinical responses of MCL patients treated with involved-field radiation therapy (IFRT) predominantly for local control and/or palliation...
  26. doi request reprint Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Neurooncol 91:315-21. 2009
    ..There was no significant cognitive decline up to 24 months post-chemotherapy and reduced-dose WBRT in this group of PCNSL patients, however, difficulties in Verbal Memory and Motor speed persisted over the follow-up period...
  27. doi request reprint High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
    Craig H Moskowitz
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Br J Haematol 148:890-7. 2010
    ..61. Risk-adapted augmentation of salvage treatment in patients with HL is feasible and improves EFS in poorer-risk patients. Our data suggest that normalisation of FI pre-ASCT predicts outcome, and should be the goal of salvage treatment...
  28. doi request reprint Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients
    Jurgen Rademaker
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1270 York Ave, New York, NY 10021, USA
    AJR Am J Roentgenol 191:32-7. 2008
    ....
  29. pmc Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
    Alison J Moskowitz
    Medical Oncology Hematology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 8, New York, NY 10065, USA
    Br J Haematol 146:158-63. 2009
    ..Future studies should focus on prospectively evaluating RIT following HDT-ASCT failure in patients with remission duration from HDT-ASCT of >6 months...
  30. doi request reprint Imaging of late complications from mantle field radiation in lymphoma patients
    Sandra Brennan
    Department of Radiology, Memorial Sloan Kettering Cancer Center, Weil Medical College of Cornell University, New York, NY 10021, USA
    Radiol Clin North Am 46:419-30, x. 2008
    ..Dedicated imaging approaches have been developed to evaluate late radiation effects on these structures...
  31. doi request reprint Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma
    Karyn A Goodman
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:5240-7. 2008
    ....
  32. doi request reprint Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy
    Meltem Ekenel
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 113:1025-31. 2008
    ..Therefore, a retrospective study was conducted to assess the impact of consolidation treatment after a CR to initial induction chemotherapy on disease control and survival...
  33. ncbi request reprint Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease
    Craig H Moskowitz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, PO Box 350, New York, NY 10021, USA
    Br J Haematol 124:645-52. 2004
    ..001). While patients with chemosensitive disease have an excellent outcome with HDT and ASCT, novel approaches are needed to cure HD patients who fail front-line and second-line chemotherapy...
  34. ncbi request reprint Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease
    Carol S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    Br J Haematol 125:701-8. 2004
    ..CD20(+) cHD is a poor prognostic factor for TTF and OS. All cHD cases should be immunophenotyped for CD20. A large prospective trial is needed to confirm these findings...
  35. ncbi request reprint Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
    David J Straus
    Memorial Sloan Kettering Cancer Center, SR 441B Box 406, 1275 York Ave, New York, NY 10021, USA
    Blood 104:3483-9. 2004
    ..Although significant differences were not seen, it is possible that a benefit in outcome of less than 20% for CMT might be seen in a larger trial...
  36. ncbi request reprint Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999
    Paul A Hamlin
    Medicine Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 130:691-9. 2005
    ....
  37. ncbi request reprint Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy
    Ariela Noy
    Lymphoma Disease Management Team and Laboratroy of Molecular Hemato Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:3768-72. 2005
    ..We have previously demonstrated long-term pathologic remission after involved-field radiotherapy therapy (IFRT). We determined molecular remission status by clonotypic polymerase chain reaction (PCR)...
  38. ncbi request reprint Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
    Tarun Kewalramani
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 103:3684-8. 2004
    ..25). RICE appears to induce very high CR rates in patients with relapsed and refractory DLBCL; however, further studies are necessary to determine whether this treatment regimen will improve outcomes after ASCT...
  39. ncbi request reprint Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells
    Shoshana Paglin
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 65:11061-70. 2005
    ..Taken together, these experiments show that radiation-induced inhibition of rapamycin-sensitive pathway in MCF-7 cells causes changes in mitochondria metabolism, development of autophagy, and an overall decrease in cell survival...
  40. ncbi request reprint FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases
    K P Beal
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Oncol 16:473-80. 2005
    ..Thus we reviewed the findings of FDG-PET scans in patients with extranodal MZL seen at our center...
  41. ncbi request reprint Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4570-4. 2006
    ..The purpose of this report is to update the initial results and provide long-term data regarding overall survival, patterns of relapse, and the risk of treatment-related neurotoxicity...
  42. ncbi request reprint Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma
    Tarun Kewalramani
    Hematology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 134:202-7. 2006
    ..The outcome of ASCT for patients with chemosensitive relapsed or primary refractory PTCL is similar to that for patients with DLBCL...
  43. ncbi request reprint Radiation-induced salivary gland tumors: a report of 18 cases and a review of the literature
    Kathryn P Beal
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer J 9:467-71. 2003
    ..The purpose of this study was to examine the relationship between radiation exposure and subsequent development of salivary gland tumors (SGTs)...
  44. ncbi request reprint Intensity-modulated tangential beam irradiation of the intact breast
    L Hong
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 44:1155-64. 1999
    ..To evaluate the potential benefits of intensity modulated tangential beams in the irradiation of the intact breast...
  45. ncbi request reprint Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma
    A D Zelenetz
    Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Ann Oncol 14:i5-10. 2003
    ..This resulted in an increased complete remission rate. Additional follow-up is necessary to determine if this improvement in the complete remission rate will confer an increase in the overall survival following SCT...
  46. ncbi request reprint Retinopathy in survivors of primary central nervous system lymphoma
    Sean A Grimm
    Memorial Sloan Kettering Cancer Center, Department of Neurology, 1275 York Avenue, New York, NY 10021, USA
    Neurology 67:2060-2. 2006
    ..We describe five patients with long-term primary CNS lymphoma who were diagnosed with retinopathy several years after treatment with chemotherapy and WBRT...
  47. ncbi request reprint Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers
    Kenneth Offit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3813-9. 2002
    ..We next sought to determine the frequency of ATM variants in patients with Hodgkin's lymphoma, regardless of coexisting BC, compared with healthy volunteers...
  48. ncbi request reprint Intensity-modulated radiotherapy for lymphoma involving the mediastinum
    Karyn A Goodman
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 62:198-206. 2005
    ....
  49. pmc Extranodal MALT Lymphoma of the Right Triceps Muscle following Influenza Vaccine Injection: A Rare Case with an Interesting Presentation
    S M Edwards-Bennett
    Department of Radiation Oncology, H Lee, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    ISRN Hematol 2011:617293. 2011
    ..She was treated with single modality, involved field radiation therapy (IFRT) to 4000 cGy in 20 fractions with excellent response and no evidence of disease after one year followup...
  50. ncbi request reprint A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles
    S Paglin
    Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:439-44. 2001
    ....
  51. doi request reprint Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: a systematic review
    Justin E Bekelman
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 73:492-8. 2009
    ..Although radiotherapy (RT) is an important component of curative therapy for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), we postulated that RT reporting may be inadequate in Phase III HL and NHL trials...
  52. ncbi request reprint Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma
    Stefan K Barta
    Department of Medicine, St Luke s Roosevelt Hospital Center, New York, NY, USA
    Clin Lymphoma Myeloma 7:77-82. 2006
    ..There is no established approach to the management of paraneoplastic cholestasis. We postulate that single-modality radiation therapy alone should be considered a valid treatment alternative in early-stage HL with idiopathic cholestasis...
  53. doi request reprint Low-dose and limited-volume radiotherapy alone for primary dural marginal zone lymphoma: treatment approach and review of published data
    Dev R Puri
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 71:1425-35. 2008
    ..We set out to analyze our recent experience in treating PDMZL and reviewed the limited published data available...
  54. ncbi request reprint Radiation treatment planning techniques for lymphoma of the stomach
    Cesar Della Biancia
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 62:745-51. 2005
    ....
  55. pmc Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study
    Elena B Elkin
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 29:2466-73. 2011
    ..To compare characteristics and outcomes of breast cancer in women with and without a history of radiation therapy (RT) for Hodgkin's lymphoma (HL)...
  56. ncbi request reprint Breast cancer after Hodgkin disease: hope for a safer cure
    Joachim Yahalom
    JAMA 290:529-31. 2003
  57. ncbi request reprint Hodgkin disease/lymphoma
    Richard T Hoppe
    Stanford Comprehensive Cancer Center, USA
    J Natl Compr Canc Netw 6:594-622. 2008
  58. ncbi request reprint Non-Hodgkin's lymphomas
    Andrew D Zelenetz
    J Natl Compr Canc Netw 6:356-421. 2008
  59. ncbi request reprint Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma
    Joachim Yahalom
    J Clin Oncol 24:544-8. 2006
  60. ncbi request reprint Advances in biology, diagnostics, and treatment of Hodgkin's disease
    Ralf Kuppers
    Institute for Cell Biology, Tumor Research, University of Duisburg Essen, Germany
    Biol Blood Marrow Transplant 12:66-76. 2006
    ....
  61. ncbi request reprint NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer
    Donald A Podoloff
    J Natl Compr Canc Netw 5:S1-22; quiz S23-2. 2007
    ..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...
  62. ncbi request reprint Pathways that regulate autophagy and their role in mediating tumor response to treatment
    Shoshana Paglin
    The Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
    Autophagy 2:291-3. 2006
    ..Future analysis of the interrelationship among these events and the role each of them plays in cell survival following radiation will increase our ability to employ the mTOR pathway in anti-cancer therapy...
  63. ncbi request reprint Multiple myeloma. Clinical practice guidelines in oncology
    Kenneth C Anderson
    J Natl Compr Canc Netw 5:118-47. 2007
  64. ncbi request reprint Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology
    Andrew D Zelenetz
    J Natl Compr Canc Netw 4:258-310. 2006
  65. ncbi request reprint Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002
    Andres J M Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Via Olgettina 60, 20132, Milan, Italy
    J Clin Oncol 21:2407-14. 2003
    ..This article summarizes the contents of the Workshop, analyzes the current knowledge on the most relevant biologic and clinical issues in PCNSL, and focuses on fundamental challenges to be addressed in future studies...
  66. ncbi request reprint Clinical practice. Superior vena cava syndrome with malignant causes
    Lynn D Wilson
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA
    N Engl J Med 356:1862-9. 2007
  67. ncbi request reprint The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort
    Philip Bretsky
    University of Southern California Norris Comprehensive Cancer Center, Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA
    Cancer Epidemiol Biomarkers Prev 12:733-8. 2003
    ..Although a single missense variant (L546V) appeared to act as a modest predictor of risk, the remaining variants were no more common in breast cancer cases as compared with controls...
  68. doi request reprint Cancer Survivorship. Preface
    Lois B Travis
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human ServicesNational Institutes of Health, Bethesda, MD, USA
    Hematol Oncol Clin North Am 22:xi-xii. 2008
  69. doi request reprint Cancer survivorship: facing forward
    Lois B Travis
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, National Institutes of Health, Bethesda, MD, USA
    Hematol Oncol Clin North Am 22:365-71, ix. 2008
    ..In this article, the authors briefly review the history of the efforts that served to coalesce efforts to champion survivorship research, identify future challenges, and provide a perspective on future recommendations...
  70. ncbi request reprint Hodgkin disease/lymphoma. Clinical practice guidelines in oncology
    Richard T Hoppe
    J Natl Compr Canc Netw 4:210-30. 2006